The Company

RetinalGeniX Technologies, Inc. is an emerging medical device company focused on commercializing the next generation of cost-effective, ultra-wide imaging technologies:

  • to examine the periphery of the retina, at up to a 200° field of view
  • to detect early signs of diabetic retinopathy and maculopathy
  • without having to dilate a patient's pupil

There is a need for a simpler and more affordable device and method that allows for simplified but accurate imaging of a person’s retina to detect symptoms of diabetic retinopathy.

 


Diabetes is a growing epidemic in the United States and abroad.

US: CDC  National Diabetes Statistics Report, 2020
  34.2 M Americans have diabetes  / 10.5% of the population
(26.8M diagnosed, 7.3M undiagnosed)
  88 M American adult have pre-diabetes

 

Global: 2019 Report: International Diabetes Foundation
  2019 – 463 M adults had diabetes
  2045 – 700 M adults projected to have diabetes

 

Being overweight or obese greatly increases your risk of developing Type 2 diabetes.
Recent research suggests that obese people are up to 80 times more likely to develop type 2 diabetes than those with a BMI of less than 22.   Jan 15, 2019, www.diabetes.co.uk

Diabetic retinopathy is a degenerative disease of the retina, which is the layer of receptors in the eyes that receive light and pass the signals to the brain via the optic nerve.  As the retina degenerates patients experience loss of vision due to bleeding, retinal detachment, and other factors.  

  • Left untreated diabetic retinopathy can lead to permanent blindness.
  • Detected early and treated, retinopathy and maculopathy can be stopped so that vision can be maintained.